HUTCHMED (China) Management
Management criteria checks 3/4
HUTCHMED (China)'s CEO is Wei-Guo Su, appointed in Jan 2012, has a tenure of 12.92 years. total yearly compensation is $2.45M, comprised of 32.5% salary and 67.5% bonuses, including company stock and options. directly owns 0.49% of the company’s shares, worth HK$98.60M. The average tenure of the management team and the board of directors is 6.6 years and 7.8 years respectively.
Key information
Wei-Guo Su
Chief executive officer
US$2.5m
Total compensation
CEO salary percentage | 32.5% |
CEO tenure | 12.9yrs |
CEO ownership | 0.5% |
Management average tenure | 6.6yrs |
Board average tenure | 7.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$42m |
Mar 31 2024 | n/a | n/a | US$29m |
Dec 31 2023 | US$2m | US$798k | US$101m |
Sep 30 2023 | n/a | n/a | US$36m |
Jun 30 2023 | n/a | n/a | -US$29m |
Mar 31 2023 | n/a | n/a | -US$195m |
Dec 31 2022 | US$4m | US$700k | -US$361m |
Sep 30 2022 | n/a | n/a | -US$308m |
Jun 30 2022 | n/a | n/a | -US$255m |
Mar 31 2022 | n/a | n/a | -US$235m |
Dec 31 2021 | US$3m | US$395k | -US$195m |
Sep 30 2021 | n/a | n/a | -US$187m |
Jun 30 2021 | n/a | n/a | -US$178m |
Mar 31 2021 | n/a | n/a | -US$151m |
Dec 31 2020 | US$1m | US$346k | -US$126m |
Sep 30 2020 | n/a | n/a | -US$117m |
Jun 30 2020 | n/a | n/a | -US$110m |
Mar 31 2020 | n/a | n/a | -US$102m |
Dec 31 2019 | US$1m | US$274k | -US$106m |
Sep 30 2019 | n/a | n/a | -US$93m |
Jun 30 2019 | n/a | n/a | -US$87m |
Mar 31 2019 | n/a | n/a | -US$83m |
Dec 31 2018 | US$1m | US$273k | -US$75m |
Sep 30 2018 | n/a | n/a | -US$72m |
Jun 30 2018 | n/a | n/a | -US$61m |
Mar 31 2018 | n/a | n/a | -US$39m |
Dec 31 2017 | US$2m | US$310k | -US$27m |
Compensation vs Market: Wei-Guo's total compensation ($USD2.45M) is above average for companies of similar size in the Hong Kong market ($USD482.18K).
Compensation vs Earnings: Wei-Guo's compensation has been consistent with company performance over the past year.
CEO
Wei-Guo Su (66 yo)
12.9yrs
Tenure
US$2,451,164
Compensation
Dr. Wei-Guo Su, B.Sc., Ph D., has been the Chief Executive Officer of HUTCHMED (China) Limited since March 04, 2022. Dr. Su has been the Chief Scientific Officer and Executive Vice President of HUTCHMED (C...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, Chief Scientific Officer & Executive Director | 12.9yrs | US$2.45m | 0.49% HK$ 98.6m | |
CFO & Executive Director | 16.4yrs | US$962.15k | 0.18% HK$ 36.4m | |
Company Secretary & Non-Executive Director | 18.9yrs | no data | no data | |
Executive VP & Head of Operations | less than a year | no data | no data | |
Head of Investor Relations & Capital Strategies | no data | no data | no data | |
Group General Counsel | 9.6yrs | no data | no data | |
Senior Vice President of Corporate Management & Communications | 1.9yrs | no data | no data | |
Senior Vice President of Global Human Resources | 2.9yrs | no data | no data | |
Senior Vice President of Business Development & Strategic Alliances | no data | no data | no data | |
Executive Vice President of Pharmaceutical Science & Manufacturing | 12.9yrs | no data | no data | |
Senior Vice President of Global Quality | 3.7yrs | no data | no data | |
Executive VP | 2.3yrs | no data | no data |
6.6yrs
Average Tenure
59yo
Average Age
Experienced Management: 13's management team is seasoned and experienced (6.6 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, Chief Scientific Officer & Executive Director | 7.8yrs | US$2.45m | 0.49% HK$ 98.6m | |
CFO & Executive Director | 13.9yrs | US$962.15k | 0.18% HK$ 36.4m | |
Company Secretary & Non-Executive Director | 18.9yrs | no data | no data | |
Non-Executive Chairman | 8.3yrs | no data | 0.013% HK$ 2.6m | |
Non-Executive Director | 1.4yrs | no data | no data | |
Independent Non-Executive Director | 7.8yrs | US$111.00k | 0.0053% HK$ 1.1m | |
Senior Independent Non-Executive Director | 7.8yrs | US$117.00k | 0.0087% HK$ 1.7m | |
Independent Non-Executive Director | 7.2yrs | US$114.86k | 0.011% HK$ 2.3m | |
Independent Non-Executive Director | less than a year | no data | no data | |
Independent Non-Executive Director | less than a year | no data | no data |
7.8yrs
Average Tenure
64.5yo
Average Age
Experienced Board: 13's board of directors are considered experienced (7.8 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/24 11:10 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
HUTCHMED (China) Limited is covered by 46 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Jiangqiao Tong | BOCI Research Ltd. |
Linda Lu | BOCI Research Ltd. |
Alec Stranahan | BofA Global Research |